Pegapamodutide

N/A

Report date: 2024/10/11 10:43:33
NME

Base Information

Drug NamePegapamodutide
Drug Alias NameOxyntomodulin analogWG4ID2U7FTOPK-88003TT-401LY-2944876 +[6] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon receptor agonistsGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucagon receptor
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandRomania +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCombiphar IncLeadermed Group LtdOpko Health Inc
Active IndicationsN/A
Inactive IndicationsObesityDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A